Intensive-dose statin therapy may pose higher diabetes risk among patients
NEW YORK — It seems that intensive-dose statin therapy is linked with a higher risk of onset diabetes, compared with moderate-dose therapy, according to an analysis published in the Journal of the American Medical Association.
The analysis, which pooled data from previously published clinical trials, found that among 32,752 nondiabetic participants:
2,749 participants (8.4%) developed diabetes. Among them, 1,449 were assigned intensive-dose therapy, while 1,300 assigned moderate-dose therapy;
6,684 (20.4%) experienced a major cardiovascular event: 3,134 assigned intensive-dose therapy, 3,550 assigned moderate-dose therapy; and
There were 149 more cases of incident diabetes in participants assigned to intensive statin treatment than in those receiving moderate therapy and 416 fewer patients with cardiovascular events who received intensive-dose therapy.
The researchers, led by David Preiss of the University of Glasgow, United Kingdom, pooled the data from five statin trials that met criteria for inclusion in the analysis.
"Our findings suggest that clinicians should be vigilant for the development of diabetes in patients receiving intensive statin therapy," the authors wrote. "In conclusion, this meta-analysis extends earlier findings of an increased incidence of diabetes with statin therapy by providing evidence of a dose-dependent association."
Diabetic kidney disease on rise in United States
NEW YORK — Despite the expansion of the diabetes drug market over the past 20 years, the rate of diabetic kidney disease has become more prevalent in the United States.
According to a new study published in the Journal of the American Medical Association, lead study author Ian de Boer and fellow researchers found that although more people in the country are being diagnosed with diabetes, and more diabetes drugs are on the market, there has been no progress in curbing kidney disease in the diabetes population. de Boer noted that diabetic kidney disease accounts for almost half of the cases of end-stage kidney failure in the United States, while approximately 60% of patients with end-stage kidney disease die within five years of onset, he said.
de Boer, who also serves as assistant professor of medicine in the division of nephrology at the Kidney Research Institute, as well as an adjunct assistant professor of epidemiology at the University of Washington in Seattle, said that diabetic kidney disease occurs develops in about 40% of people with diabetes.
"Improvements in reaching therapeutic targets in diabetes management have not translated into a decline in diabetic kidney disease," de Boer said. "The results of our research don’t suggest that standards of diabetes care for controlling blood sugar levels, high blood pressure, and cholesterol should be changed. What the findings suggest is that these treatments alone are not doing an effective job of reducing diabetic kidney disease, and researchers need to find additional ways to do that," de Boer said.
At shareholders meeting, Kroger emphasizes focus on customers
CINCINNATI — Kroger CEO David Dillon said the company will continue to focus on customer loyalty, after reporting last week that it saw identical-store sales increase for 30 consecutive quarters.
During its shareholders meeting on Thursday, Dillon said the company will build its future growth around its Customer 1st strategy, which emphasizes "[our] people, products, prices and the shopping experience."
"Our strategy is really to grow our relevancy to our customers," Dillon was quoted as saying by the Associated Press. "That becomes our bigger mission; to the extent that leads to new markets, great."
Amid its positive first-quarter results, Kroger last week increased its earnings guidance to $1.85 to $1.95 per diluted share for the full year.
In related news, Kroger declared a quarterly dividend of 10.5 cents, payable on Sept. 1 to shareholders of record on Aug. 15.